Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Lapatinib is a HER1 and HER2 tyrosine kinase inhibitor (TKI) approved in second line treatment of advanced or metastatic breast cancer following progression on trastuzumab-containing therapy. Biomarkers for activity of lapatinib and other TKIs are lacking. Formalin-fixed, paraffin-embedded primary t...

Descripción completa

Detalles Bibliográficos
Autores principales: Duchnowska, Renata, Sperinde, Jeff, Czartoryska-Arłukowicz, Bogumiła, Myśliwiec, Paulina, Winslow, John, Radecka, Barbara, Petropoulos, Christos, Demlova, Regina, Orlikowska, Marlena, Kowalczyk, Anna, Lang, Istvan, Ziółkowska, Barbara, Dębska-Szmich, Sylwia, Merdalska, Monika, Grela-Wojewoda, Aleksandra, Żawrocki, Anton, Biernat, Wojciech, Huang, Weidong, Jassem, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732794/
https://www.ncbi.nlm.nih.gov/pubmed/29262628
http://dx.doi.org/10.18632/oncotarget.22027

Ejemplares similares

Ejemplares similares